Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
Jun 14, 2024 → Oct 1, 2026
NCT ID
NCT06334133About Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + Placebo
Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + Placebo is a phase 3 stage product being developed by vTv Therapeutics for Diabetes Mellitus, Type 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06334133. Target conditions include Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06334133 | Phase 3 | Recruiting |
Competing Products
20 competing products in Diabetes Mellitus, Type 1